Table 3. Reported studies of PD-L1 in NSCLC.
Author | Year | N | Population | PDL1 assay | PD-L1% | Cutoff % | Findings |
---|---|---|---|---|---|---|---|
Taube [31] | 2014 | 41 | Mixed histology | 5H1, M3 | 53 | 5 | Associated with TILsPredict response to chemotherapy |
Azuma[44] | 2014 | 164 NSCLC | Asian57% EGFR mutated Stage I-III | Lifespan Bio-sciences | Median | Associated with AC histology & EGFR mutation. | |
Konishi[40] | 2004 | 52 | Asian Stage I-III | M1H1 | Median | No relationship to clinical outcomes observed | |
Kim[45] | 2015 | 331 SCC | Asian Stage I-III | Cell Signalling | 27 | 10 | Correlated with CD8+ TILs Not associated with survivalCD8+ TILs correlated with improved survival |
D’Incecco[33] | 2015 | 125 NSCLC | Stage IVItalian | Abcam | 55 | 5 | Associated with AC histology, EGFR mutation. |
Boland[46] | 2013 | 214SCC | Caucasian Stage I-IV | Dako | 19 | 1 | No relationship to clinical outcomes observed. |
Zhang[30] | 2014 | 143 AC | Asian Stage I-III | Sigma-Aldrich | Median | Worse survival outcomes if PD-L1 positive | |
Velcheti[41] | 2013 | 544 NSCLC | 2 cohorts Caucasian & Greek Stage I-IV | Dr. Lieping Chen’s lab (5H1) | 26, 35 | Correlated with TILs Improved OS with PD-L1 expression (independent) | |
Yang[47] | 2014 | 163 AC | Stage I Asian | Proteintech | 40 | 5 | Improved DFS PD-L1 positive No improved OS but very few deaths |
Cooper[42] | 2015 | 681 NSCLC | Caucasian Stage I-III | Merck | 8 | 50 | Improved OS PD-L1 positive in SCC, not in AC. |
Schmidt | 2015 | 321 NSCLC | Caucasian Stage I-III | Cell Signalling | 24 | 5 | Improved OS PD-L1 positive in SCC, adjuvant therapy, T2-T4 and N1-N3 disease. |
AC adenocarcinoma; SCC squamous cell carcinoma; NSCLC non-small cell lung cancer; OS overall survival; DFS disease free survival; EGFR epidermal growth factor receptor; TILs tumor infiltrating lymphocytes.